Literature DB >> 24397396

Bisphenol A (BPA) and its potential role in the pathogenesis of the polycystic ovary syndrome (PCOS).

Aleksandra Rutkowska1, Dominik Rachoń.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common and the most heterogeneous endocrine disorder in premenopausal women. Apart from signs of hyperandrogenism such as acne, hirsutism and hair loss, women with PCOS usually present with menstrual irregularities and fertility problems.Additionally, they are often characterized by impaired glucose tolerance, which usually leads to the development of type 2 diabetes mellitus (T2DM). This review article describes current and novel approach to the pathomechanisms of PCOS and the potential role of an endocrine disrupting chemical ("endocrine disruptor" - ED) - bisphenol A (BPA), which is commonly used as a plasticizer and due to its molecular structure can interact with estrogen receptors (ERs). Recent observations point to the higher levels of BPA in biological fluids of women with PCOS and its role in the pathogenesis of hyperandrogenism and hyperinsulinemia. It seems that mother's exposure to BPA during pregnancy may also lead to the development of PCOS in the female offspring.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24397396     DOI: 10.3109/09513590.2013.871517

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  19 in total

Review 1.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

Review 2.  Recent advances in simultaneous analysis of bisphenol A and its conjugates in human matrices: Exposure biomarker perspectives.

Authors:  Syam S Andra; Christine Austin; Juan Yang; Dhavalkumar Patel; Manish Arora
Journal:  Sci Total Environ       Date:  2016-08-30       Impact factor: 7.963

Review 3.  Long-term effects of early-life exposure to environmental oestrogens on ovarian function: role of epigenetics.

Authors:  G Cruz; W Foster; A Paredes; K D Yi; M Uzumcu
Journal:  J Neuroendocrinol       Date:  2014-09       Impact factor: 3.627

Review 4.  Developmental programming of insulin resistance: are androgens the culprits?

Authors:  Muraly Puttabyatappa; Robert M Sargis; Vasantha Padmanabhan
Journal:  J Endocrinol       Date:  2020-06       Impact factor: 4.286

5.  Metabolic and endocrine effects of bisphenol A exposure in market seller women with polycystic ovary syndrome.

Authors:  Mahjoob Vahedi; Arastoo Saeedi; Seyedeh Leila Poorbaghi; Masood Sepehrimanesh; Mohammadreza Fattahi
Journal:  Environ Sci Pollut Res Int       Date:  2016-09-10       Impact factor: 4.223

6.  Soy but not bisphenol A (BPA) induces hallmarks of polycystic ovary syndrome (PCOS) and related metabolic co-morbidities in rats.

Authors:  Heather B Patisaul; Natalie Mabrey; Heather B Adewale; Alana W Sullivan
Journal:  Reprod Toxicol       Date:  2014-09-19       Impact factor: 3.143

Review 7.  EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals.

Authors:  A C Gore; V A Chappell; S E Fenton; J A Flaws; A Nadal; G S Prins; J Toppari; R T Zoeller
Journal:  Endocr Rev       Date:  2015-11-06       Impact factor: 19.871

Review 8.  Review on bisphenol A and the risk of polycystic ovarian syndrome: an insight from endocrine and gene expression.

Authors:  Risani Mukhopadhyay; Navya B Prabhu; Shama Prasada Kabekkodu; Padmalatha S Rai
Journal:  Environ Sci Pollut Res Int       Date:  2022-02-24       Impact factor: 5.190

Review 9.  Endocrine disrupting chemicals (EDCs) and female cancer: Informing the patients.

Authors:  Dominik Rachoń
Journal:  Rev Endocr Metab Disord       Date:  2015-12       Impact factor: 6.514

10.  Induction of the Estrogenic Marker Calbindn-D₉k by Octamethylcyclotetrasiloxane.

Authors:  Dongoh Lee; Changhwan Ahn; Beum-Soo An; Eui-Bae Jeung
Journal:  Int J Environ Res Public Health       Date:  2015-11-17       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.